FDA starts review of Sanofi's oral type 1 diabetes drug - PMLiVE
A Type 1 Diabetes Pill? Newest Sotagliflozin Trial Results
Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor - Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands, 2015
Sotagliflozin for the Treatment of Heart Failure, US
The Year SGLT2 Inhibitors Became Full-Fledged Heart Failure Drugs | MedPage Today
Now Approved | INPEFA™ (sotagliflozin)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INPEFA safely and effect
Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine? | Nature Cardiovascular Research
Sotagliflozin for the Treatment of Heart Failure, US
Muthu Vaduganathan on Twitter: "Sotagliflozin (INPEFA) receives *broad* @US_FDA approval based on #SOLOISTWHF & #SCORED to reduce CV death, HF hosp, & urgent HF visits in either: HF or T2D, CKD, and
Diabetes Care | Don Valley Pharma
ESC 2021: Eli Lilly, Boehringer's Jardiance racks up data for 2nd nod in crowded heart failure field | Fierce Pharma
SGLT2 Inhibitors Added to ESC Guidelines for Treatment of Chronic HFrEF
Pragati Arora on LinkedIn: #diabetescare #diabetesmanagement #healthcare #marketing #brandmanagement
PDF) Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor
SGLT Inhibition--It's Not Just for Type 2 Anymore: JDRF Reports
Bayer's Kerendia to compete against SGLT-2 inhibitors < Pharma < Article - KBR
Inpefa: Package Insert / Prescribing Information - Drugs.com
Sotagliflozin Approved in EU for Adults With Type 1 Diabetes
The 5 Developing Type 2 Diabetes Treatments You Should Know About - GoodRx
Lexicon Pharmaceuticals, Inc. Trademarks & Logos
Sotagliflozin – Wikipedia
ACC: Lexicon hopes sotagliflozin cardio data will set its drug apart from SGLT2 rivals | Fierce Pharma
Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor - Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands, 2015
Federal Register/Vol. 86, No. 40/Wednesday, March 3, 2021/Notices
